Gene writer genome engineering for in vivo car-t
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042590015
- Awardee
-
Tessera Therapeutics, Inc. UEI XFPJKGA6ARL1
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $11,891,248
Award facts
- Contract value 29% obligated
-
- $11,891,248.00 Current, with exercised options
- $41,342,707.00 Potential, with all options
- Completion date 18% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Somerville, MA 02143, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $11,891,248 |
About this award
The National Institutes of Health awarded Tessera Therapeutics, Inc., a federal contract worth $41.3 million to develop Gene Writer genome engineering technology for in vivo CAR-T cell therapy applications. The contract, structured as an Other Transaction Agreement and awarded on September 23, 2025, represents the NIH's investment in advancing cell and gene therapy approaches, which are among the agency's priority research areas. The work will be performed at Tessera's facility in Somerville, Massachusetts, with an ultimate completion date of September 22, 2031. This award was not designated as a set-aside contract.
This contract supports NIH's broader mission to advance biomedical innovation by funding development of genetic engineering technologies that could enable CAR-T cells to be modified directly within the body, potentially improving the safety and efficacy of cancer immunotherapy treatments. The six-year timeline reflects the substantial research and development effort required to translate genome engineering capabilities into viable therapeutic applications, while the Other Transaction Agreement structure provides the flexibility often needed for emerging biotechnology development.
Quick answers
Who was awarded contract 140D042590015?
140D042590015 was awarded to Tessera Therapeutics, Inc. by Interior Business Center (Office of Policy Management and Budget) on September 23, 2025.
How much is contract 140D042590015 worth?
The government has obligated $11,891,248 on 140D042590015. Its potential value, with all options, is $41,342,707.
Which agency awarded contract 140D042590015?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042590015, with funding from National Institutes of Health (Department of Health and Human Services).
Was contract 140D042590015 competed?
The extent of competition for 140D042590015 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award